{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Naghavi-Behzad M"],"funding":["NCI NIH HHS","This study was supported by the Centre for Personalized Response Monitoring in Oncology (Odense University Hospital, Denmark) and the University of Southern Denmark."],"pagination":["1271-1279"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9042860"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["126(9)"],"pubmed_abstract":["<h4>Background</h4>We compared overall survival for metastatic breast cancer (MBC) patients monitored with CE-CT, FDG-PET/CT or a combination of them in an observational setting.<h4>Methods</h4>Patients with biopsy-verified (recurrent or de novo) MBC (n = 300) who were treated at Odense university hospital (Denmark) and response monitored with FDG-PET/CT (n = 83), CE-CT (n = 144), or a combination of these (n = 73) were followed until 2019. Survival was compared between the scan groups, and were adjusted for clinico-histopathological variables representing potential confounders in a Cox proportional-hazard regression model.<h4>Results</h4>The study groups were mostly comparable regarding baseline characteristics, but liver metastases were reported more frequently in CE-CT group (38.9%) tha"],"journal":["British journal of cancer"],"pubmed_title":["Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT."],"pmcid":["PMC9042860"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Olsen MMB","Asmussen JT","Vach W","Hildebrandt MG","Kodahl AR","Kidholm K","Vester RM","Oltmann H","Gerke O","Weber W","Vogsen M","Naghavi-Behzad M","Braad PE"],"additional_accession":[]},"is_claimable":false,"name":"Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.","description":"<h4>Background</h4>We compared overall survival for metastatic breast cancer (MBC) patients monitored with CE-CT, FDG-PET/CT or a combination of them in an observational setting.<h4>Methods</h4>Patients with biopsy-verified (recurrent or de novo) MBC (n = 300) who were treated at Odense university hospital (Denmark) and response monitored with FDG-PET/CT (n = 83), CE-CT (n = 144), or a combination of these (n = 73) were followed until 2019. Survival was compared between the scan groups, and were adjusted for clinico-histopathological variables representing potential confounders in a Cox proportional-hazard regression model.<h4>Results</h4>The study groups were mostly comparable regarding baseline characteristics, but liver metastases were reported more frequently in CE-CT group (38.9%) tha","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-21T21:18:52.629Z","creation":"2025-04-05T18:19:21.224Z"},"accession":"S-EPMC9042860","cross_references":{"pubmed":["35013575"],"doi":["10.1038/s41416-021-01654-w"]}}